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ABSTRACT
Background: X linked intellectual disability (XLID)
syndromes account for a substantial number of males
with ID. Much progress has been made in identifying
the genetic cause in many of the syndromes described
20–40 years ago. Next generation sequencing (NGS)
has contributed to the rapid discovery of XLID genes
and identifying novel mutations in known XLID genes
for many of these syndromes.
Methods: 2 NGS approaches were employed to
identify mutations in X linked genes in families with
XLID disorders. 1 involved exome sequencing of genes
on the X chromosome using the Agilent SureSelect
Human X Chromosome Kit. The second approach was
to conduct targeted NGS sequencing of 90 known
XLID genes.
Results: We identified the same mutation, a c.12928
G>C transversion in the HUWE1 gene, which gives rise
to a p.G4310R missense mutation in 2 XLID disorders:
Juberg-Marsidi syndrome ( JMS) and Brooks
syndrome. Although the original families with these
disorders were considered separate entities, they
indeed overlap clinically. A third family was also found
to have a novel HUWE1 mutation.
Conclusions: As we identified a HUWE1 mutation in
an affected male from the original family reported by
Juberg and Marsidi, it is evident the syndrome does
not result from a mutation in ATRX as reported in the
literature. Additionally, our data indicate that JMS and
Brooks syndromes are allelic having the same HUWE1
mutation.
INTRODUCTION
In the two decades since the discovery of the
trinucleotide repeat expansion in FMR1
responsible for fragile X syndrome, substan-
tial progress has been made in deﬁning the
other X linked intellectual disability (XLID)
syndromes at the molecular level.1–3
Mutations in over 100 X-chromosome genes
have been assigned at least provisional roles
in these syndromes.2 4 Some syndromes, ini-
tially believed to be separate conditions, have
now been lumped together while others that
appeared to be the same have been sepa-
rated on the basis of molecular
ﬁndings.2 3 5 6
Juberg-Marsidi syndrome ( JMS) has here-
tofore been considered by some observers to
be allelic to α-thalassemia intellectual disabil-
ity (ATRX syndrome) while Brooks syndrome
(aka Brooks-Wisniewski-Brown syndrome) has
been considered to be distinct from JMS.7–10
A missense mutation in ATRX has been previ-
ously reported in a family considered to have
JMS.8 On clinical re-evaluation of the ori-
ginal family reported by Juberg and Marsidi,7
we considered the ﬁndings in the sole
affected male still alive to be inconsistent
with ATRX syndrome. While there are some
similarities between JMS and ATRX syn-
drome, there are distinctive differences.7
Speciﬁcally, the surviving male in the
Strengths and limitations of this study
▪ Using the power of next generation sequencing,
we have linked Juberg-Marsidi syndrome ( JMS)
and Brooks syndrome as allelic conditions.
▪ This study provides better organisation to the
field of X linked disorders by providing evidence
that JMS is not caused by mutation in the ATRX
gene.
▪ We provide clinical descriptions and compari-
sons to support our conclusions.
▪ The reported missense mutations have detrimen-
tal effects on HUWE1 functional activity.
▪ Based on the limited number of patients/families,
we are unable to make specific genotype–pheno-
type correlations at this time.
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Juberg-Marsidi family had bifrontal narrowing, hypote-
lorism, prominent nose with overhanging columella,
and thin lips, all facial manifestations very different than
those of ATRX syndrome. Subsequently, we identiﬁed in
this male, a novel missense alteration in HUWE1, a gene
located at Xp11.23 that encodes an E3 ubiquitin ligase
that regulates numerous proteins, such as key cellular
factors p53 and Mcl1.11 12 The identical missense alter-
ation in HUWE1 was also identiﬁed and shown to prop-
erly segregate in another XLID syndrome reported by
Brooks et al.10 The clinical phenotypes in the two condi-
tions previously considered to be unrelated show close
similarity. Here, we update the clinical and molecular
ﬁndings in these two families and report an additional
family with another missense mutations in HUWE1.
METHODS
Informed consent
The authors note that we have obtained proper
informed consent from the participants (or parental
consent for participants under 18 years of age) for use
of their personal information, including photos, for pub-
lication purposes. Copies of these consents have been
shared with the ofﬁce of the Editor.
Families
Clinical update: K9149 (original JMS family)
Clinical ﬁndings in four affected males in three genera-
tions included generalised growth retardation, severe
intellectual disability, tall forehead, epicanthus, short
palpebral ﬁssures, pale retina, ﬂat nasal bridge, large or
cupped ears, small penis with undescended testes and
deafness.7 The two brothers in generation II died in
infancy or childhood.
The pedigree and clinical ﬁndings were updated in
2006. The nephew (III-2 in ﬁgure 1A), age 27 years, was
found to have moderate hearing loss of unknown type
but believed to be related to recurrent otitis media,
severe growth impairment (all measurements below the
third centile) and intellectual disability (IQ<20).
Craniofacial ﬁndings included facial asymmetry, bifron-
tal narrowing, furrowing of the forehead, prominent
brow giving the eyes and midface a sunken appearance,
hypotelorism, upslanting palpebral ﬁssures, prominent
nose with overhanging columella, long philtrum and
thin lips with a beak at the midpoint of the upper lip
(ﬁgure 1). Additional features were brachydactyly,
decreased musculature of the distal legs, foot deform-
ation (right foot everted, left foot with midfoot varus),
scoliosis, ﬂexion of the hips, genu vara, soft loose skin
over the hands and hyperextensible joints. Sexual hair
and penis appeared normal but the testes were not palp-
able. He had no speech, but uttered sounds when under
stress and used gestures to indicate his desires (table 1).
All females, including two obligate and four non-
obligate carriers identiﬁed by gene testing, had normal
growth, craniofacial appearance and intellectual
function. Marked skewing (>90:10) of X chromosome
inactivation in all carrier females provided a plausible
reason for absence of clinical manifestations. One
carrier subsequently had an affected son. He had
growth retardation when delivered at 38 weeks with a
weight of 1510 g, head circumference of 30 cm and
length of 42 cm, all measurements less than the third
centile for 38 weeks. He had hypotelorism, small appear-
ing eyes, ﬂat nasal bridge, right cleft lip and palate,
supravalvar aortic stenosis, small hands and feet, exter-
nally rotated feet and undescended testes. Ultrasound
examination of the brain showed a small cyst
(1.0×1.6 cm) within each lateral ventricle. He failed the
newborn hearing test.
Clinical update: K9223 (original Brooks syndrome family)
Clinical ﬁndings in two affected brothers and a nephew
were generalised intrauterine and postnatal growth
retardation, severe intellectual disability, triangular-
shaped face, low posterior hairline, bifrontal narrowness,
malar ﬂatness, blepharophimosis, optic atrophy, esotro-
pia, nystagmus, bulbous nose, low-set and cupped ears,
short philtrum, thin tented upper lip and pectus excava-
tum (ﬁgure 1B).10 They were poorly coordinated and
became self-abusive, hyperactive and spastic with large
joint contractures.
The pedigree and clinical ﬁndings were updated in
2010. The affected males were aged 23, 45 and 52 years.
All growth parameters remained well below the third
centile. Affected males became ambulatory by about age
3 years, but remained non-verbal or had very limited
speech (table 1). Hearing loss was believed to be related
to recurrent otitis media. Cranial imaging showed
enlarged ventricles and small brain.
Three carrier females had normal intellectual func-
tion and showed no phenotypic abnormalities.
X-inactivation was markedly skewed (>90:10) in the two
carriers who were informative at the AR locus.
Clinical report: family 3
Family 3 consists of two brothers, now aged 10 and
13 years (II-5 and II-4 in ﬁgure 1C), who have severe
intellectual disability, microcephaly and postnatal growth
failure. The brothers have three sisters, one of whom
has minor literacy problems. Their mother also has a
minor learning difﬁculty, not present in her three broth-
ers and sister. X-inactivation testing in the mother and
the daughter with literacy problems was uninformative.
The two brothers were born at term gestation with
weights and lengths at term at or below the third
centile, being 2.52 and 2.67 kg and 44 and 47 cm,
respectively. Neither was microcephalic at birth but have
been less than third centile since early childhood. Early
motor milestones were delayed with both boys not
walking independently until after age 2 years. The oldest
brother had tight Achilles tendons and required serial
casting and ankle-foot orthoses. His gait was broad based
and ataxic, with reduced extension of hips and knees.
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The younger brother had better language skills, with
over 100 single words, and could follow single step com-
mands; the older brother only had a few single words.
Both brothers had early onset growth failure, with sig-
niﬁcant short stature. Their heights were more than
−4.0 SD from the mean by age 3 years. Dynamic testing
excluded growth hormone deﬁciency (peak growth
hormone levels 54.3 and 13.9 mIU/L to glucagon stimu-
lation). Alternative causes of short stature were not iden-
tiﬁed. Both boys were treated with and responded to
growth hormone, with their heights now approaching
the third centile. Neither boy had clinical or biochem-
ical evidence of other endocrine abnormalities. Their
genitalia were normal and the older brother had normal
pubertal development. The youngest brother has astig-
matism, but otherwise vision and hearing in both boys is
normal.
Both brothers are now markedly microbrachycephalic,
with head circumference of 47 cm (less than third
centile) and 48 cm (less than third centile), respectively.
They have sparse scalp hair, which was more obvious in
early infancy. Craniofacial features include deep-set eyes,
broad nasal bridge and nasal tip, a wide mouth, a thin
upper lip and prognathism (ﬁgure 1C and table 1). The
older brother’s ears are cupped, his eyebrows are thick
and his face is now coarse, resembling the pictures of
the patient with JMS (ﬁgure 1A).
Skeletal surveys in both boys demonstrated only bra-
chycephaly and delayed bone age (prior to treatment
with growth hormone). Neuroimaging showed some
increased extra-axial space and ventriculomegaly; white
matter loss in the parietal, occipital and periventricular
regions; a normal pituitary gland and a posterior pituit-
ary bright spot.
Figure 1 Pedigrees of families with HUWE1 mutations. (A) Pedigree of K9149. Photographs show microcephaly, cupped ears
and thin upper lip in infant (II-6); and 27-year-old nephew (III-2) from original family reported by Juberg and Marsidi.7 (B)
Pedigree of family K9223. Photographs show microcephaly, cupped ears, blepharophimosis, deeply set eyes, depressed nasal
bridge and bulbous nasal tip in affected male (III-1) from original family reported by Brooks et al10 at age 4 months and 4 years.
(C) Pedigree of family 3. The affected boys’ mother (I-2) and one sister (II-2) have mild learning disabilities. Photographs show
microcephaly, frontal hair upsweep, deep-set eyes, broad nasal tip, wide mouth, thin upper lip and prominent jaw in brothers,
ages 10 (II-5) and 13 years (II-4). The older brother also has cupped ears, thick eyebrows and coarse face. +, presence of
mutation; −, normal; , proband; , affected; , carrier.
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Table 1 Comparison of findings in families with missense mutations and duplications of HUWE1*
Juberg and
Marsidi7 Brooks et al10 Family 3 Froyen et al22 Isrie et al24 Mattei et al9
K9149 K9223 A323 UK444 UK106 Dup
HUWE1
ATRX mutation
Affected individuals 4M 3M 2M 4M 3M 3M 24M 2M 7M
Mutation p.G4310R p.G4310R p.R4063Q p.R4013W p.R4187C p.R2981H Dup p.R4013W p.R1272Q
Low birth weight
(<3c)
4/4 3/3 2/2 0/1 – – 0/12 – 2/2
Low birth length
(<3c)
4/4 – 2/2 – – – 0/1 – 1/2
Short stature (<3c) 4/4 3/3 2/2 – 1/1 – 0/19 0/2 –
Microcephaly (<3c) 4/4 3/3 2/2 0/4 0/1 0/1 1/19 0/2 1/2
Macrocephaly
(>97c)
0/4 0/3 0/2 2/4 0/1 0/1 0/19 0/2 0/2
Strabismus 2/3 2/3 – – 1/1 – 1/11 0/2 –
Epicanthus 2/2 3/3 – – – – 3/8 0/2 1/1
Deep-set eyes 1/1 3/3 2/2 – – – 0/8 1/2 –
Blepharophimosis/
small pf
4/4 3/3 – – – – 3/8 0/2 1/1
Cupped ears 1/3 2/3 2/2 0/4 – 1/2 3/8 0/2 0/1
Prominent nose 1/3 3/3 2/2 0/3 – – 3/8 0/2 0/1
Thin lip(s) 2/3 3/3 2/2 1/3 – – 0/9 – 0/1
Undescended
testes
4/4 – 0/2 0/1 – – 0/8 – 2/3
Deafness 4/4 1/3 0/2 1/4 – – 0/20 – 1/3
Seizures 1/4 0/3 0/2 0/4 – – 0/8 – –
Hypotonia 1/4 0/3 0/2 1/1 – – 5/11 – 1/1
Severe ID (IQ<50) 4/4 3/3 2/2 4/4 – – 12/17 2/2 3/3
Absent/limited
speech

















*The de novo p.V950A mutation in one of two brothers with autism reported by Nava et al25 is not included because of lack of clinical details.






























As the clinical evaluation of K9149, the original
Juberg-Marsidi family was not consistent with ATRX syn-
drome and sequencing of ATRX conducted at the
Greenwood Genetic Center failed to detect a mutation,
marker analysis using 28 X-chromosome markers was
performed.13
Sequencing
Genomic DNA from affected male, III-2, in family K9149
was enriched for exons of 718 genes on the X chromo-
some using the Agilent SureSelect Human X
Chromosome Kit and subjected to next generation
sequencing (NGS) as previously described.14 DNA from
affected male, III-1, was enriched for 90XLID genes
using RainDance microdroplet technology (RainDance
Technologies, Lexington, Massachusetts, USA).
Sequencing of these 90 genes was performed on an
Applied Biosystems SOLiD 3 Plus Sequencer.
Preparation of whole cell extracts
Lymphoblastoid cells were collected and washed twice
with ice cold phosphate buffered saline (PBS), followed
by ﬂash freezing of the cell pellet in liquid N2.
Subsequently, the thawed cells were resuspended in one
packed cell volume (PCV) of lysis buffer I (10 mM
Tris-HCl pH 7.8, 200 mM KCl, 1 mM N-ethylmaleimide
(NEM), 0.1 mM MG-132, 1 μM PMSF, 2 μM leupeptin,
3 μM bestatin, 1.5 μM pepstatin) and two PCVs of lysis
buffer II (10 mM Tris-HCl pH 7.8, 600 mM KCl, 2 mM
EDTA, 40% glycerol, 0.2% NP-40, 1 mM NEM, 0.1 mM
MG-132, 1 μM phenylmethylsulfonyl ﬂuoride (PMSF),
2 μM leupeptin, 3 μM bestatin, 1.5 μM pepstatin). The
samples were further incubated for 30 min at 4°C, soni-
cated and centrifuged. The supernatants were either
stored at −80°C or used directly for immunoblot analysis.
Immunoblotting
High molecular weight proteins present in the whole
cell extract were separated on a 7% Tris-acetate poly-
acrylamide (PA) gel, while lower molecular weight pro-
teins (p53 and Mcl-1) were separated by a 10%
Tris-glycine PA gel. After separation, proteins were trans-
ferred to an Immobilon-FL membrane (Millipore), fol-
lowed by subsequent immunoblotting. Primary
antibodies against HUWE1 (Bethyl Laboratories), p53
(Santa Cruz) and Mcl-1 (BD Pharmingen) were
detected using infrared (IR) dye-conjugated secondary
antibodies (Rockland). The signal was visualised using
direct IR ﬂuorescence via the Odyssey Scanner (LI-COR
Biosciences).
shRNA knockdown
Cells from male control were lentivirally transduced with
plasmids carrying the non-speciﬁc control shRNA
(pGIPZ-Ns, Open Biosystems) or the mule-targeting
shRNA (GIPZ Human HUWE1 shRNA, Clone-ID
V3LHS_353153, Open Biosystems). Stable clones were
subsequently selected with puromycin, while the selec-
tion efﬁciency was monitored by the percentage of
green ﬂuorescent protein (GFP)-positive cells.
RESULTS
Segregation analysis in K9149 of 28 markers spaced
along the X chromosome indicated four markers from
DX51055 (Xp11.2) to AR (Xq12) were linked to JMS
(data not shown). The region did not include the ATRX
gene conﬁrming the negative gene sequencing and clin-
ical impression that JMS was not allelic to ATRX. But as
the region contained many genes, NGS of exons on the
X chromosome was initiated.
NGS of genes on the X chromosome in individual
III-2 identiﬁed only one unique variant within the
‘linked’ interval, a G>C transversion at nucleotide 12928
(c.12928G>C) in HUWE1. This change results in a mis-
sense mutation, p.G4310R. The ﬁnding was conﬁrmed
by Sanger sequencing. The alteration segregated with
the phenotype (ﬁgure 1A) as expected since HUWE1 is
within the ‘linked’ interval.
NGS of individual III-1 in family K9223 for 90 XLID
genes identiﬁed the same missense HUWE1 mutation as
the only unique change after other single nucleotide
polymorphisms were removed from further consider-
ation based on available database and in-house fre-
quency information. Sanger sequencing conﬁrmed the
NGS ﬁnding and the alteration segregated properly in
the family (ﬁgure 1B). The Sorting Intolerant From
Tolerant (SIFT), PolyPhen-2 and Mutation Taster predic-
tion algorithms indicated that replacing a non-polar
amino acid with one that is charged is not expected to
be tolerated, consistent with a damaging effect on the
protein (see online supplementary table S1).
The older brother, II-4, in family 3 was found to have
a mutation in HUWE1 (c.12188G>A; p. R4063Q) by an x
exome analysis. This mutation alters a highly conserved
amino acid in the HECT domain. The mutation arose as
a de novo event in the mother and is also present in her
other affected son as well as two of her daughters
(ﬁgure 1C). Neither this alteration nor the shared
variant for families 1 and 2 has been reported in the
available databases, including the Exome Variant Server
database that includes exome data for approximately
6500 individuals.
In order to determine if the p.G4310R mutation
affected the HUWE1 function, protein levels were com-
pared between the cells derived from an affected male
(ﬁgure 1A, III-2) from the original JMS family (K9149)
and the cells from a healthy male family member
(ﬁgure 1A, IV-1). As shown in ﬁgure 2, the amount of
HUWE1 in cells from the affected male was signiﬁcantly
reduced to approximately 39% of the HUWE1 level in
the cells from the healthy relative (ﬁgure 1A, IV-1). The
levels of two important HUWE1 substrates, Mcl1 and
p53, were signiﬁcantly increased in the patient’s cells
(ﬁgure 3). To conﬁrm that reduced HUWE1 levels
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directly cause the upregulation in p53 and Mcl1 levels,
we performed HUWE1 knock-down experiments in cells
from healthy individuals. On HUWE1 knock-down, we
observed an accumulation in Mcl1 and p53, thus indicat-
ing that the change in HUWE1 status is directly corre-
lated with changes in p53 and Mcl1 levels (see online
supplementary ﬁgure S1). Taken together, these ﬁndings
suggest that p. G4310R mutation identiﬁed in the
affected male from the JMS family (K9149) leads to
reduced E3 ligase levels and consequent accumulation
of downstream targets p53 and Mcl1.
In family 3, levels of the HUWE1 p.R4063Q protein
were increased, and consequently the levels of p53 sub-
strate were reduced in the two affected brothers com-
pared with their normal father (ﬁgure 4). Taken
together, altered levels of mutant HUWE1 proteins and
Figure 2 E3 ubiquitin ligase HUWE1 protein level is decreased in the affected male, III-2, from family K9149. (A) Immunoblot
analysis of the HUWE1 protein level a lymphoblastoid cell line from the affected male (figure 1A, III-2) and in a normal male in
the family (figure 1A, IV-1). The star indicates unspecific bands. (B) Quantification of three independent experiments as the one
presented in (A); error bars indicate mean±SD; **p<0.01.
Figure 3 Protein levels of well-known HUWE1 substrates are upregulated in the affected male III-2, from family K9149.
Immunoblot analysis of Mcl-1 (A) and p53 (C) protein levels in a normal male in the family (figure 1A, IV-1) and a lymphoblastoid
cell line from the affected male (family 1A, III-2). (B) and (D) Quantification of three independent experiments as the ones
presented in (A) and (C), respectively; error bars indicate mean±SD; *p<0.05.
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as a consequence, the levels of its target substrates
suggest that missense changes potentially affect HUWE1
function.
DISCUSSION
HUWE1 plays a role in various essential physiological pro-
cesses by regulating the stability of multiple proteins.
Initially, HUWE1 was shown to bind the tumour suppres-
sor p53, thus inhibiting transactivation.11 15 Further
HUWE1 was shown through ubiquitylation to contribute
to regulation of the antiapoptotic protein Mcl1.12
Additional substrates of HUWE1 include proteins such as
histones,16 transcription factor Miz1,17 DNA polymerases
β and λ,18 19 topoisomerase TopBP1,20 and others.
Among the 200 named XLID syndromes, a number of
entities have been found to be allelic using molecular
technologies.2 3 5 6 Prominent among these are
PQBP1-associated XLID (Renpenning, Sutherland-Haan,
Hamel Cerebro-Palato-Cardiac, Golabi-Ito-Hall and
Porteous syndromes), ATRX-associated XLID (ATRX syn-
drome, Carpenter-Waziri, Holmes-Gang, Chudley-Lowry
and XLID-Hypotonia-Arch Fingerprints syndromes) and
ARX-associated XLID (Partington, West, Lissencephaly
and Abnormal Genitalia, and Hydranencephaly with
Abnormal Genitalia syndromes).
In 1983, Mattei et al9 reported an XLID family with
seven affected males which they considered to have JMS.
Villard et al8 found a missense mutation in the helicase
domain of ATRX in the family, and since that time JMS
has been called an ATRX-associated XLID syndrome in
much of the literature. Our clinical re-evaluation of the
surviving male in the original JMS family showed ﬁnd-
ings that were not consistent with ATRX-associated
XLID, speciﬁcally bifrontal narrowing, hypotelorism,
prominent nose and thin lips, prompting us to question
their conclusion. Sequencing of the ATRX gene in this
male failed to ﬁnd a pathogenic alteration (data not
shown). Further, review of the males reported by Mattei
et al9 shows them to have clinical ﬁndings very different
from JMS and more consistent with ATRX-associated
XLID (table 1).
The availability of NGS provided an opportunity to
sequence 718 X-chromosome genes simultaneously in the
surviving affected member of the Juberg-Marsidi family.
This effort identiﬁed a missense mutation in HUWE1
(c.12928G>C; p.G4310R) which was considered to be
likely disease causing (Mutation Taster), not tolerated
(SIFT) and probably damaging (PolyPhen-2; ﬁgure 5 and
online supplementary table S1). Functional studies per-
formed on a cell line from the surviving affected male in
the original family with JMS showed signiﬁcantly
decreased HUWE1 protein levels and consequently
increased levels of two well-known substrates, p53 and
Mcl-1, as compared with a normal family member
(ﬁgures 3 and 4).
This molecular ﬁnding clearly establishes JMS as an
XLID disorder caused by a mutation in HUWE1 rather
than in ATRX. The same mutation was also found in the
family reported by Brooks et al10 using a 90-gene XLID
panel (see online supplementary table). Comparisons of
the phenotype of Juberg-Marsidi and Brooks syndromes
convinced us that they were examples of the same syn-
drome clinically. We have been unable to link the two
Figure 4 Functional assessment of the p.R4063Q HUWE1
mutation in family 3. HUWE1 protein levels are increased in
p.R4063Q lymphoblastoid cell lines (LCLs) derived from the
affected brothers and results in moderate reduction in the
levels of the p53 protein. Unaffected father I-1 (lane 1),
affected sons, II-3 and II-4 (lanes 2 and 3). Total LCL protein
lysates were western blotted and probed for HUWE1, p53 and
B-tubulin (loading control).
Figure 5 Domains and missense mutations found in HUWE1 with the relative boundaries of each domain indicated. The known
missense alterations are shown below the DUF4414 and HECT domains. The p.G4310R mutation reported in this paper is in
red. The WWE domain is named for its conserved residues and is predicted to mediate specific protein–protein interactions in
ubiquitin and ADP-ribose conjugation systems. The C-terminal catalytic HECT belongs to a subclass of ubiquitin-protein E3
ligases. DUF913 belongs to a family found in various ubiquitin protein ligases and DUF4414 is in a family of domains frequently
found in DNA-binding proteins of the URE-B1 type. DUF, domains of unknown function.
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kindreds through ancestry or common area of residence.
A third family was also found to have a slightly more
proximal missense mutation (p.R4063Q) which altered
a highly conserved arginine in the HECT domain,
which was likewise predicted to be deleterious (see
online supplementary table S1). HUWE1 p.R4063Q
protein had increased stability and p53 levels reduced in
the lymphoblast cell lines derived from the affected
males in this family. Vandewalle et al21 recently reported
that an extra dose of HUWE1 affects axon branching of
dorsal cluster neurons of Drosophila melanogaster through
the Wnt/3-catenin pathway.
It appears that the phenotypic spectrum resulting from
HUWE1 mutations is quite broad table 1. The
Juberg-Marsidi-Brooks phenotype appears most severe
with marked growth impairment, somatic manifestations,
absent or limited speech and delayed ambulation. Two
other families (families A323 and UK444 of Froyen
et al22) are less severely affected, having normal or large
head circumference, minimal facial dysmorphism and
milder intellectual disability.23 It is of interest that carrier
females in families with less severe phenotypic expression
may have mild expression, not being protected by skewed
inactivation of their affected X chromosome. The loca-
tion of the mutations in the reported cases does not
suggest an obvious explanation for the phenotypic vari-
ability. The mutation in Juberg-Marsidi-Brooks syndrome
is located in the HECT domain (the catalytic domain of
the HUWE1 ubiquitin protein ligase) as are the muta-
tions in the third family reported here and in the more
mildly affected UK444 family.22 The other two missense
mutations in HUWE1, the p.R2981H mutation in a
severely affected family and the p.R4013W mutation in a
family with a less severe phenotype, are located between
the WWE and HECT domains.22 Further cases with
HUWE1 mutations will be necessary to determine if a
genotype–phenotype correlation can be made.
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